CEMI News Chembio to Host Conference Call to Discuss Marketing Partner Agreements for Rapid HIV Tests
NEW YORK--(BUSINESS WIRE)--Chembio Diagnostics, Inc. (OTCBB:CEMI)
will host a conference call on Tuesday, October 10th
at 4:30pm EST. The call will be held to discuss the marketing partner
agreements, for their rapid HIV tests, and financing that was announced
earlier today. A live web cast can be accessed by clicking on the
following link http://www.vcall.com/IC/CEPage.asp?ID=109970.
A recording of this web cast can also be accessed using the same link.
ABOUT CHEMBIO
Chembio Diagnostics, Inc., a developer and manufacturer of rapid
diagnostic tests for infectious diseases, is on the frontlines of the
global battle against the AIDS pandemic. The Company has received
marketing approval from the FDA for its SURE CHECK®
HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also
manufactures rapid tests for veterinary Tuberculosis and Chagas Disease,
and has developed a patent-pending technology, the Dual Path Platform
(DPP(TM)), for its next generation HIV and other rapid tests. For
additional information please visit www.chembio.com.
FORWARD-LOOKING STATEMENTS
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of
1933, as amended. Forward-looking statements include statements
regarding the intent, belief or current expectations of the Company and
its management. Such statements are estimates only, as the Company has
not completed the preparation of its financial statements for those
periods, nor has its auditor completed the audit of those results.
Actual revenue may differ materially from those anticipated in this
press release. Such statements reflect management's current views, are
based on certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and
will be dependent upon a variety of factors, including, but not limited
to Chembio's ability to obtain additional financing, to obtain
regulatory approvals in a timely manner, and the demand for Chembio's
products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after the date hereof or to reflect any change in Chembio's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact Chembio's success are more
fully disclosed in Chembio's most recent public filings with the U.S.
Securities and Exchange Commission.
